SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)

For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the trea...

Descripción completa

Detalles Bibliográficos
Autor principal: Omrčen, Tomislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2022
Materias:
Professional Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022414/
https://www.ncbi.nlm.nih.gov/pubmed/36938560
http://dx.doi.org/10.20471/acc.2022.61.s3.12
_version_ 1784908726520512512
author Omrčen, Tomislav
author_facet Omrčen, Tomislav
author_sort Omrčen, Tomislav
collection PubMed
description For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.
format Online
Article
Text
id pubmed-10022414
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
record_format MEDLINE/PubMed
spelling pubmed-100224142023-03-18 SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) Omrčen, Tomislav Acta Clin Croat Professional Papers For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC. Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2022-10 /pmc/articles/PMC10022414/ /pubmed/36938560 http://dx.doi.org/10.20471/acc.2022.61.s3.12 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Professional Papers
Omrčen, Tomislav
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title_full SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title_fullStr SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title_full_unstemmed SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title_short SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
title_sort systemic triple therapy in metastatic hormone sensitive prostate cancer (mhspc)
topic Professional Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022414/
https://www.ncbi.nlm.nih.gov/pubmed/36938560
http://dx.doi.org/10.20471/acc.2022.61.s3.12
work_keys_str_mv AT omrcentomislav systemictripletherapyinmetastatichormonesensitiveprostatecancermhspc

Ejemplares similares